Adial Pharmaceuticals (ADIL) Stock Price, News & Analysis

Company Overview

Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative treatments for alcohol dependence and other substance use disorders. The company’s lead product candidate, known as AD04, is a nalmefene-based therapy designed to modulate gene expression pathways implicated in alcohol craving and relapse. Adial leverages proprietary gene expression blockade technology to develop a pipeline of differentiated drug candidates aimed at addressing critical unmet needs in addiction medicine.

Founded in the mid-2000s, Adial Pharmaceuticals has progressed its lead program through preclinical research into early-phase human trials, with the goal of demonstrating safety, tolerability and efficacy in patients suffering from alcohol use disorder. In addition to its work on AD04, the company has initiated exploratory studies in related areas of substance abuse, including cocaine dependence, to broaden its therapeutic reach. Adial’s R&D efforts are supported by collaborations with academic research centers and independent clinical investigators.

Headquartered in North America, Adial maintains operations in the United States and Canada and is pursuing strategic partnerships to facilitate future clinical development and potential commercial access in Europe and Asia. The company’s multidisciplinary team includes experts in neuroscience, regulatory affairs and clinical pharmacology, positioning Adial to navigate the complex regulatory landscape for addiction therapies. Adial also engages with patient advocacy groups to ensure that its clinical programs align with patient needs and standards of care.

Under the leadership of a seasoned management team with deep experience in biotech and pharmaceutical development, Adial Pharmaceuticals continues to advance toward late-stage clinical evaluation. The company’s commitment to scientific rigor and its focus on addressing the societal burden of addiction underscore its mission to deliver novel, effective treatment options for patients worldwide.

Key Stats

• Today's Range: $0.37 to $0.40
• 50-Day Range: $0.23 to $0.73
• 52-Week Range: $0.22 to $3.00
• Volume: 1.77 million shs
• Average Volume: 3.00 million shs
• Market Capitalization: $4.02 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.00
• Consensus Rating: Strong Buy

Adial Pharmaceuticals Stock Analysis - MarketRank™

Adial Pharmaceuticals scored higher than 50% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Strong Buy

Consensus Rating

Adial Pharmaceuticals has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Adial Pharmaceuticals has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Adial Pharmaceuticals are expected to grow in the coming year, from ($1.53) to ($1.33) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Adial Pharmaceuticals is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Adial Pharmaceuticals is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Adial Pharmaceuticals has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.48% of the float of Adial Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Adial Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Adial Pharmaceuticals has recently increased by 90.51%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Adial Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Adial Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

6.48% of the float of Adial Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Adial Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Adial Pharmaceuticals has recently increased by 90.51%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.52

News Sentiment

Adial Pharmaceuticals has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.00 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Adial Pharmaceuticals this week, compared to 1 article on an average week.

Search Interest

15 people have searched for ADIL on MarketBeat in the last 30 days. This is an increase of 1,400% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Adial Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Adial Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.26% of the stock of Adial Pharmaceuticals is held by insiders.

Percentage Held by Institutions

Only 16.41% of the stock of Adial Pharmaceuticals is held by institutions.

ADIL Stock Analysis - Frequently Asked Questions

How have ADIL shares performed this year?

Adial Pharmaceuticals' stock was trading at $1.01 at the beginning of the year. Since then, ADIL stock has decreased by 61.9% and is now trading at $0.3850.

How were Adial Pharmaceuticals' earnings last quarter?

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) posted its quarterly earnings results on Wednesday, May, 14th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.50) by $0.16.

When did Adial Pharmaceuticals' stock split?

Shares of Adial Pharmaceuticals reverse split on the morning of Monday, August 7th 2023.The 1-25 reverse split was announced on Monday, August 7th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

When did Adial Pharmaceuticals IPO?

Adial Pharmaceuticals (ADIL) raised $8 million in an IPO on Friday, July 27th 2018. The company issued 1,500,000 shares at $5.00 per share. Joseph Gunnar & Co. served as the underwriter for the IPO and Dawson James Securities was co-manager.

How do I buy shares of Adial Pharmaceuticals?

Shares of ADIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Adial Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Adial Pharmaceuticals investors own include NVIDIA (NVDA), Adobe (ADBE), Broadcom (AVGO), CrowdStrike (CRWD), CymaBay Therapeutics (CBAY), Arista Networks (ANET) and GE Aerospace (GE).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 7/12/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ADIL
• CIK: 1513525
• Web: www.adialpharma.com
• Phone: (434) 422-9800
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Adial Pharmaceuticals: $8.00
• High Price Target: $8.00
• Low Price Target: $8.00
• Potential Upside/Downside: +1,977.9%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 3.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.46)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$13.20 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -218.88%
• Return on Assets: -177.61%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.99
• Quick Ratio: 1.99

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.64 per share
• Price / Book: 0.60

Miscellaneous

• Outstanding Shares: 10,440,000
• Free Float: 9,990,000
• Market Cap: $4.02 million
• Optionable: No Data
• Beta: 1.02